Evidence map›Paper›PMID 40471367›Full record

ArticleMolecular biomedicine2025

Transmembrane emp24 domain-containing protein 3 promotes the malignant progression of glioma by regulating the ZBTB7A signaling axis.

Yang Qiao, Lv Zhou, Jianyu Nie, Jinshui Li, Yangchun Hu, Peng Gao, Bingshan Wu, Hongwei Cheng, Xingliang Dai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yang Qiao *Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230001, China.
Lv Zhou *Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230001, China.
Jianyu NieDepartment of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230001, China.
Jinshui LiDepartment of Clinical Medicine, the Second Clinical College of Anhui Medical University, Hefei, Anhui, 230032, China.
Yangchun HuDepartment of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230001, China.
Peng GaoDepartment of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230001, China.
Bingshan WuDepartment of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230001, China. wubingshan@gmail.com.
Hongwei ChengDepartment of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230001, China. hongwei.cheng@ahmu.edu.cn.
Xingliang DaiDepartment of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230001, China. daixingliang@ahmu.edu.cn.ORCID http://orcid.org/0000-0002-0685-4766

Funding

Anhui Medical University Anhui Medical University Scientific Research FundAnhui Medical University Clinical Cooperative ResearchAnhui Medical University Promotion Program of Anhui Medical UniversityAnhui Medical University the BasicAnhui Provincial Department of Science and Technology Research Fund of Anhui Institute of Translational MedicineNational Natural Science Foundation of China National Natural Science FoundationNatural Science Foundation of Anhui Province anhui province natural science foundationScientific Research Foundation of Education Department of Anhui Province of China Anhui Provincial Department of Education Higher Education Quality Engineering ProjectScientific Research Foundation of Education Department of Anhui Province of China Anhui Provincial Department of Education University Research Program Project
6 · The paper itself

Abstract

Glioblastoma (GBM) is highly malignant with a poor prognosis. Exploring new therapeutic targets in GBM is an effective strategy for the prognosis of GBM patients. The Transmembrane emp24 domain-containing protein 3 (TMED3) gene has been found to play a role in the development of various cancers, but its mechanism in GBM remains unclear. This study combined the TCGA database, single-cell RNA sequencing, and in vitro and in vivo experiments to systematically investigate the role of TMED3 in GBM and its potential mechanisms. The study found that the TMED3 gene is differentially expressed in GBM samples, and high expression is associated with a higher grade of GBM and a poorer prognosis. In vitro and in vivo experiments confirmed that the upregulation of TMED3 promoted GBM proliferation, invasion, and migration. Further immunoprecipitation and functional rescue experiments revealed that Zinc finger and BTB domain-containing protein 7A (ZBTB7A) acts as a downstream target of TMED3. TMED3 promotes the malignant progression of GBM by regulating ZBTB7A. In conclusion, this study reveals that TMED3 promotes GBM development through the regulation of the ZBTB7A signaling axis, providing new insights for targeted therapy of GBM.

Indexed as

Brain NeoplasmsDNA-Binding ProteinsGlioblastomaGliomaMembrane ProteinsSignal TransductionTranscription FactorsAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleDNA-Binding ProteinsMembrane ProteinsTranscription FactorsZBTB7A protein, humanGlioblastoma (GBM)Single-Cell SequencingTarget therapyTransmembrane emp24 domain-containing protein 3 (TMED3)Zinc finger and BTB domain-containing protein 7A (ZBTB7 A)

Identifiers

PMID40471367
PMCPMC12141185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.